University of Miami Sylvester Comprehensive Cancer Center
13
4
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
62.5%
-24.1% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Role: collaborator
African Cancer Genome: GMD
Role: collaborator
A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer
Role: collaborator
Together After Cancer
Role: collaborator
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
Role: collaborator
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
Role: lead
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Role: collaborator
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
Role: collaborator
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
Role: collaborator
Vorinostat in Patients With Class 2 High Risk Uveal Melanoma
Role: collaborator
Mohs and Immunofluorescence for Malignant Melanoma In Situ
Role: collaborator
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Role: collaborator
Redes II National Patient Navigator Intervention Study
Role: collaborator
All 13 trials loaded